Affordable Access

Publisher Website

Protein methyltransferase inhibitors as personalized cancer therapeutics

Authors
Journal
Drug Discovery Today Therapeutic Strategies
1740-6773
Publisher
Elsevier
Volume
9
Identifiers
DOI: 10.1016/j.ddstr.2011.08.001
Disciplines
  • Biology
  • Chemistry
  • Medicine

Abstract

The protein methyltransferases (PMTs) have emerged as a novel target class, especially for oncology indications where specific genetic alterations, affecting PMT activity, drive cancer tumorigenesis. This target class has proved quite druggable; small molecule inhibitors (PMTis) of several PMT enzymes have been reported, that display a diversity of chemical structures and target binding modalities. Here we review recent progress in identifying, characterizing and optimizing PMTis for eventual use as personally targeted cancer therapeutics.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments